Deep-tissue localization of magnetic field hyperthermia using pulse sequencing

Tansi, Felista L.; Maduabuchi, Wisdom O.; Hirsch, Melanie; Southern, Paul; Hattersley, S; Quaas, Rainer; Teichgräber, Ulf; Pankhurst, Quentin A.; Hilger, Ingrid

doi:10.1080/02656736.2021.1912412

Cited by 19 publications

(18 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last years, promising strategies to induce the photothermal effect both in vitro and in vivo have been developed, including plasmonic photothermal therapy (PPTT) [ 150 ] and red and near-infrared (NIR) laser light irradiations [ 151 ]. MNPs can also be functionalized with active compounds such as doxorubicin, gemcitabine and/or nab-paclitaxel [ 152 – 154 ], to achieve a strong synergistic cytotoxic effect, at least in preclinical models of glioblastoma and pancreatic carcinoma. Some of these preparations have reached clinical trial stages and even approval for their marketing: NanoTherm ® therapy (trade name), the first MNP based therapy for prostate and brain tumors in the world, has been recently evaluated in a clinical setting (NCT02033447 (prostate) [ 155 ] and DRKS00005476 (glioblastoma) [ 156 ] for MNPs-MH therapy.…”

Section: Magnetic Hyperthermia Applications and Autophagymentioning

confidence: 99%

Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective

et al. 2023

View full text Add to dashboard Cite

In recent years, progress in nanotechnology provided new tools to treat cancer more effectively. Advances in biomaterials tailored for drug delivery have the potential to overcome the limited selectivity and side effects frequently associated with traditional therapeutic agents. While autophagy is pivotal in determining cell fate and adaptation to different challenges, and despite the fact that it is frequently dysregulated in cancer, antitumor therapeutic strategies leveraging on or targeting this process are scarce. This is due to many reasons, including the very contextual effects of autophagy in cancer, low bioavailability and non-targeted delivery of existing autophagy modulatory compounds. Conjugating the versatile characteristics of nanoparticles with autophagy modulators may render these drugs safer and more effective for cancer treatment. Here, we review current standing questions on the biology of autophagy in tumor progression, and precursory studies and the state-of-the-art in harnessing nanomaterials science to enhance the specificity and therapeutic potential of autophagy modulators.

show abstract

Section: Magnetic Hyperthermia Applications and Autophagymentioning

confidence: 99%

Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Up to this point, no clinical studies on MHT in HGGs have surpassed this threshold; the maximum H × f used in two such trials was 1.50 × 10 9 Am −1 s [ 9 , 50 , 75 ]. Pulsed heating has been shown to minimize the non-specific eddy current heating [ 14 , 102 , 103 ]. While optimizing AMF parameters is crucial for effective MHT, it is equally important to balance these parameters within safe limits to avoid adverse effects, ensuring that the therapeutic benefits of MHT are maximized without compromising patient safety.…”

Section: Mht Workflowmentioning

confidence: 99%

Magnetic Hyperthermia Therapy for High-Grade Glioma: A State-of-the-Art Review

Rodriguez,

Rivera,

Zhang

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Magnetic hyperthermia therapy (MHT) is a re-emerging treatment modality for brain tumors where magnetic nanoparticles (MNPs) are locally delivered to the brain and then activated with an external alternating magnetic field (AMF) to generate localized heat at a site of interest. Due to the recent advancements in technology and theory surrounding the intervention, clinical and pre-clinical trials have demonstrated that MHT may enhance the effectiveness of chemotherapy and radiation therapy (RT) for the treatment of brain tumors. The future clinical success of MHT relies heavily on designing MNPs optimized for both heating and imaging, developing reliable methods for the local delivery of MNPs, and designing AMF systems with integrated magnetic particle imaging (MPI) for use in humans. However, despite the progression of technological development, the clinical progress of MHT has been underwhelming. This review aims to summarize the current state-of-the-art of MHT and offers insight into the current barriers and potential solutions for moving MHT forward.

show abstract

“…Heterogeneous MNP distribution within the tumor and the tumor microenvironment (TME) arise from aberrant tumor physiology and physical properties. New approaches are needed to achieve target hyperthermic temperatures within the TME while minimizing locally under-treated and ablative tumor zones, under-treated margins, and inadvertent heating of healthy tissue ( Moroz et al, 2002 ; Kandala et al, 2018 ; Darvishi et al, 2021 ; Singh et al, 2021 ; Tansi et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Design of a temperature-feedback controlled automated magnetic hyperthermia therapy device

Sharma

Jangam²,

Shen³

et al. 2023

Front. Therm. Eng.

View full text Add to dashboard Cite

Introduction: Magnetic hyperthermia therapy (MHT) is a minimally invasive adjuvant therapy capable of damaging tumors using magnetic nanoparticles exposed radiofrequency alternating magnetic fields. One of the challenges of MHT is thermal dose control and excessive heating in superficial tissues from off target eddy current heating.Methods: We report the development of a control system to maintain target temperature during MHT with an automatic safety shutoff feature in adherence to FDA Design Control Guidance. A proportional-integral-derivative (PID) control algorithm was designed and implemented in NI LabVIEW®. A standard reference material copper wire was used as the heat source to verify the controller performance in gel phantom experiments. Coupled electromagnetic thermal finite element analysis simulations were used to identify the initial controller gains.Results: Results showed that the PID controller successfully achieved the target temperature control despite significant perturbations.Discussion and Conclusion: Feasibility of PID control algorithm to improve efficacy and safety of MHT was demonstrated.

show abstract

Deep-tissue localization of magnetic field hyperthermia using pulse sequencing

Cited by 19 publications

References 51 publications

Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective

Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective

Magnetic Hyperthermia Therapy for High-Grade Glioma: A State-of-the-Art Review

Design of a temperature-feedback controlled automated magnetic hyperthermia therapy device

Contact Info

Product

Resources

About